Isoquinolone PI3Kα Inhibitors for Mutant-Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors for cancer therapy cause dose-dependent adverse events such as hyperglycemia, rash, fatigue, and diarrhea due to non-selective inhibition of PI3K isoforms, necessitating the development of novel, potent, and selective inhibitors to mitigate toxicity while effectively targeting cancer cells.
Innovation Solution
Development of isoquinolone compounds with specific structural modifications that selectively inhibit mutant PI3Kα isoform over wild type, reducing adverse effects on healthy cells and enhancing cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PI3K inhibitors are used to treat cancer, then cancer cell signaling is suppressed, but adverse events such as hyperglycemia, rash, fatigue, and diarrhea occur due to inhibition of healthy cells
Solution Approach 1:
The patent applies local quality by designing isoquinolone compounds with specific structural features (such as substituents at particular positions on the isoquinolone ring system) that enable selective binding to mutant PI3Kα isoforms over wild-type PI3Kα and other PI3K isoforms. This structural differentiation allows the inhibitor to exert its cancer-suppressing effect locally at mutant isoforms while sparing healthy cells with wild-type isoforms, thereby reducing adverse events.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of PI3K inhibitors through systematic variation of substituents (e.g., different groups at R1-R8 positions in the isoquinolone core) to optimize binding affinity and selectivity for mutant PI3Kα. These structural parameter modifications enable the compounds to achieve high potency against cancer cells while maintaining selectivity that reduces toxicity in healthy tissues.
2Object-affected harmful factors
If selective PI3K isoform inhibitors are developed to reduce toxicity, then adverse events are mitigated, but the complexity of inhibitor design and selection increases
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibitor design into a core isoquinolone structure with defined substitution patterns. The core structure provides the essential binding pharmacophore, while specific substituents at designated positions (R1-R8) can be systematically varied to achieve different selectivity profiles. This modular approach simplifies the design process compared to de novo creation of selective inhibitors, as the core framework is established and only specific positions need optimization.
3Object-affected harmful factors
If mutant selective PI3Kα inhibitors are used, then cancer signaling is suppressed with minimal impact on healthy cells, but the ability to treat diverse cancer types with different PI3K mutations is limited
Solution Approach 1:
The patent applies universality by developing a series of isoquinolone compounds that share a common core structure capable of binding to mutant PI3Kα isoforms across different cancer types. The systematic variation of substituents (R1-R8) allows the same core framework to be adapted for different mutant types (e.g., H1047R, E542K, E545K) and potentially other PI3K isoforms, enabling a single compound series to address multiple cancer types with different mutational profiles.
Data Source
AI summary
Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway,wherein R1 to R8 are as defined.